• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >Single dose versus fractionated stereotactic radiotherapy for meningiomas.
【24h】

Single dose versus fractionated stereotactic radiotherapy for meningiomas.

机译：脑膜瘤单剂量与分段立体定向放疗相比。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To evaluate the safety and efficacy of stereotactic radiosurgery (SRS) compared to fractionated stereotactic radiation therapy (FSRT) for meningiomas treated over a seven year period. METHODS AND MATERIALS: Of the 53 patients (15 male and 38 female) with 63 meningiomas, 35 were treated with SRS and the 18 patients with tumors adjacent to critical structures or with large tumors were treated with FSRT. The median doses for the SRS and the FSRT groups were 1400 cGy (500-4500 cGy) and 5400 cGy (4000-6000 cGy) respectively. Median target volumes for SRS and FSRT were 6.8 ml and 8.8 ml respectively. The median follow-up for the SRS and FSRT groups were 38 months (4.1-97 months) and 30.5 months (6.0-63 months) respectively. RESULTS: The five-year tumor control probability (TC) for benign versus atypical meningiomas were 92.7% vs. 31% (P = .006). The three-year TC were 92.7% vs. 93.3% for SRS vs. FSRT groups respectively (P = .62). For benign meningiomas, the three-year TC were 92.9% vs. 92.3% for the SRS group (29 patients) vs. FSRT group (14 patients) respectively (P = .77). Two patients in the SRS group and one in the FSRT group developed late complications. CONCLUSION: Preliminary data suggest that SRS is a safe and effective treatment for patients with benign meningiomas. Fractionated stereotactic radiation therapy with conventional fractionation appeared to be an effective and safe treatment alternative for patients not appropriate for SRS. A longer follow-up is required to determine the long-term efficacy and the toxicity of these treatment modalities.
机译：目的：评估立体定向放射外科（SRS）与分段立体定向放射治疗（FSRT）相比在七年内治疗的脑膜瘤的安全性和有效性。方法和材料：53例脑膜瘤患者53例（男15例，女38例）中，有35例接受了SRS治疗，对18例邻近关键结构或大肿瘤的患者采用FSRT治疗。 SRS和FSRT组的中位剂量分别为1400 cGy（500-4500 cGy）和5400 cGy（4000-6000 cGy）。 SRS和FSRT的中位目标量分别为6.8 ml和8.8 ml。 SRS和FSRT组的中位随访时间分别为38个月（4.1-97个月）和30.5个月（6.0-63个月）。结果：良性和非典型性脑膜瘤的五年肿瘤控制概率（TC）为92.7％对31％（P = .006）。 SRS组和FSRT组的三年TC分别为92.7％和93.3％（P = .62）。对于良性脑膜瘤，三年期TC分别为SRS组（29例患者）和FSRT组（14例患者）的92.9％和92.3％（P = 0.77）。 SRS组中的两名患者和FSRT组中的一名患者出现了晚期并发症。结论：初步数据表明，SRS对于良性脑膜瘤患者是一种安全有效的治疗方法。对于不适合SRS的患者，采用常规分割的立体定向放射疗法似乎是一种有效且安全的治疗选择。需要更长的随访以确定这些治疗方式的长期疗效和毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号